Relevant patient and tumor considerations for early prostate cancer treatment

Seminars in Urologic Oncology

Volumn 20, Issue 1, 2002, Pages 39-44

  Leak, Ben ^a,b,c   Wei, John T ^a,b,c   Gabel, Molly ^a,b,c   Peabody, James O ^a,b,c   Menon, Mani ^a,b,c   Demers, Raymond ^a,b,c   Tewari, Ashutosh ^a,b,c  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b Josephine Ford Cancer Center   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Modeling; Patient education; Prostate cancer; Survival

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; COMORBIDITY; DOCTOR PATIENT RELATION; EARLY CANCER; HUMAN; MALE; PATIENT COUNSELING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW;

EID: 0036166262     PISSN: 10810943     EISSN: None     Source Type: Journal    
DOI: 10.1053/suro.2002.30397     Document Type: Review

References (26)

1. Cancer statistics, 2000
2. Radical retropubic prostatectomy with reduced morbidity: An anatomic approach
3. Laparoscopic radical prostatectomy: Technique
4. The effect of patient position and treatment technique in conformal treatment of prostate cancer
5. Three dimensional conformal radiotherapy for the treatment of prostate cancer: Low risk of chronic rectal morbidity observed in a large series of patients
6. Radical radiation therapy options for organconfined prostate cancer
7. Results of conservative management of clinically localized prostate cancer
8. Long-term survival and mortality in prostate cancer treated with noncurative intent
9. The role of watchful waiting in the management of localized prostate cancer
10. Control of prostate cancer with radiotherapy: Long-term results
11. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer
12. Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia
13. Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma
14. Pretreatment prostate specific antigen doubling times: Use in patients before radical prostatectomy
15. Survival after the age of 80 in the United States, Sweden, France, England, and Japan
16. Are we selecting the right patients for treatment of localized prostate cancer? Results of an actuarial analysis
17. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
18. The impact of co-morbidity on life expectancy among men with localized prostate cancer
19. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer
20. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update
21. Prostatespecific antigen failure despite pathologically organ-confined and margin-negative prostate cancer-the basis for an adjuvant therapy trial
22. Analyzing outcome-based staging for clinically localized adenocarcinoma of the prostate
23. Assessment of outcome prediction models for localized prostate cancer in patients managed with external beam radiation therapy
24. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer
25. 20-Year outcome of patients with TI-3NO surgically staged prostate cancer treated with external beam radiation therapy
26. Natural history of progression after PSA elevation following radical prostatectomy